Breakthrough device to treat coronary heart disease is preparing for U.S. registration
The U.S. company BioVentrix is preparing to register an innovative device for the treatment of coronary heart disease. The minimally invasive Revivent TC system reduces left ventricular volume and radius by eliminating scarring in patients with systolic heart failure.BioVentrix has raised $48.5 million in venture capital funding to complete work on its innovative Revivent TC device for treating coronary heart disease. The funds should help the startup bring the development to FDA registration and bring it to the U.S. market, according to FierceBioTech.
The system uses anchors that are implanted into the damaged part of the heart, reducing the size of the ventricle. The procedure is performed in a cardiac surgical unit setting without the use of a heart-lung machine. Revivent TC can be implanted through a sternotomy or minithoracotomy and jugular access. The innovation makes it possible to eliminate the use of cardiopulmonary bypass.
Revivent TC has previously received approval in Europe, as well as breakthrough device status from an American regulator. This year, the FDA gave it the green light for use in high-risk heart failure patients.
"Treating patients with advanced heart failure by repairing the left ventricle is recognized by the clinical cardiology community as the most relevant approach," said BioVentrix President and CEO Jim Dillon.
Translated with www.DeepL.com/Translator (free version)